NCT05335473View on ClinicalTrials.gov

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

May 1, 2025

Study Completion Date

November 1, 2025

Conditions
HR Positive HER2 Negative Advanced Breast Cancer
Interventions
DRUG

Eribulin and Tucidinostat

phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat

Trial Locations (1)

Unknown

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV